HC Wainwright Reiterates "Buy" Rating for Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright's price target points to a potential upside of 167.86% from the stock's current price.

Several other equities research analysts also recently issued reports on AQST. Piper Sandler began coverage on Aquestive Therapeutics in a report on Thursday, April 11th. They set an "overweight" rating and a $10.00 price target for the company. JMP Securities increased their target price on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the company an "outperform" rating in a report on Friday, March 15th. Finally, Raymond James began coverage on shares of Aquestive Therapeutics in a report on Thursday, March 28th. They set an "outperform" rating and a $7.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of "Buy" and an average target price of $8.00.

Aquestive Therapeutics Stock Down 10.0 %

NASDAQ:AQST traded down $0.38 on Tuesday, hitting $3.36. The stock had a trading volume of 4,003,454 shares, compared to its average volume of 2,284,417. Aquestive Therapeutics has a 52 week low of $1.25 and a 52 week high of $6.23. The business's fifty day moving average is $4.20 and its 200 day moving average is $2.85. The company has a market cap of $246.29 million, a PE ratio of -24.00 and a beta of 2.87.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.04). The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $11.79 million. Equities analysts predict that Aquestive Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 25,000 shares of the business's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the transaction, the insider now directly owns 1,040,371 shares in the company, valued at $5,399,525.49. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 8.39% of the stock is owned by insiders.

Institutional Trading of Aquestive Therapeutics

A number of large investors have recently bought and sold shares of AQST. Legato Capital Management LLC purchased a new position in shares of Aquestive Therapeutics in the fourth quarter worth about $688,000. Armistice Capital LLC grew its stake in Aquestive Therapeutics by 314.5% in the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company's stock valued at $7,344,000 after buying an additional 3,642,000 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Aquestive Therapeutics by 238.8% during the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company's stock valued at $841,000 after acquiring an additional 388,017 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Aquestive Therapeutics by 14.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company's stock worth $379,000 after acquiring an additional 30,898 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $60,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.